# Single Center Clinical Experience with Hybrid Convergent Ablation and Impact on atrial fibrillation burden as determined by cardiac rhythm management devices

Mashal Tahirkheli, Arslan Ahmad, Qasim Manzoor Amjad, Hannah Hameed, Bireera Muzaffar, Sakina Batool, Sara Ahmed, Paul J. Garabelli, Hussnain Zafar, Zarrar Sani, Hunter Weitzel, Muhammad Baig M.D., Sidra Ahmad, Alysha Siddiqi, Mehak Ali, Coty W. Jewell M.D., Naeem K. Tahirkheli M.D.

# **1 INTRODUCTION**

Hybrid convergent (HC) ablation for atrial fibrillation(AF), is a closed chest epicardial and subsequent endocardial ablation, to isolate the left atrial posterior wall and pulmonary veins. The aim is to leverage the strengths of both approaches, with an intent to achieve more transmural and durable lesions. Herein, we report 264 consecutive cases from 2015 to 2019, with a mean 2-year follow-up. Almost all patients had long-term continuous monitoring devices (CRM).

## 2 OBJECTIVES

To assess the efficacy of convergent procedure in patient with atrial fibrillation monitored on long term cardiac rhythm management devices.

# **3 MATERIALS AND METHODS**

This descriptive case series study was conducted at Oklahoma Heart Hospital-South from May, 2015 to August, 2019. The study included all individuals from the hospital registry who underwent Hybrid Convergent ablation for atrial fibrillation in the above period. Data was collected retrospectively for 357 patients. The data was collected pre-procedure, during the procedure, at the time of discharge and during routine/non-routine follow-ups. The majority of patients were followed using continuous rhythm monitoring (CRM) devices for AF after the procedure. Quantitative data is presented as mean  $\pm$  SD while qualitative variables are presented as frequency and percentages. Effect modifiers are controlled through stratification and the post-stratification chi-square test was applied taking a p-value of ≤0.05 as significant. Our main outcome consisted of 4 composite variables i.e. Death, AF Burden >5%, Recurrence of symptoms, and rehospitalization for AF. Kaplan-Meir curve and cox-regression analysis was performed for the main outcome and secondary outcomes using follow-up data.

## 4 Results

357 patients were included in the study and followed for 5 years with a mean follow-up of 2.21  $\pm$  1.37 yrs. Mean age was 65  $\pm$ 10.4 years. 71.7% were male and 39.4% were female. Table 1 shows the baseline characteristics of our patients. Table 2 shows procedure data for hybrid convergence (HC). In >90% of patients all pulmonary veins were ablated. 27.3% of patients underwent LA Appendage isolation and 50% of patients underwent Roof lesion ablation. The complication rate was 3.9%. Graph 1 shows the Kaplan-Meir curve for the main outcome. Graph 2 shows the Kaplan Meir curve for primary outcome stratified based on AF classification. Graph 3A shows >80% of patients were symptom-free from AF at the end of follow-up among patients with paroxysmal and persistent AF. Cox regression analysis shows significant difference between Paroxysmal and Permanent AF with respect to main outcome variables . The best response to HC ablation is observed in paroxysmal AF. The post-stratification analysis doesn't show any significant association with comorbid and other risk factors.

٦	able 01: Baseline cha	racte		
BASELINE CHARACTERISTICS				
Mean age				
Females (%)		39		
Mean BMI		33		
	Paroxysmal	53		
ATRIAL FIBRILLATION	Persistent	20		
CLASSIFICATION	Long-Term Persistent	0.		
	Not Available	10		
CHA2DS2VASc Score				
Ejection Fraction				
Left Atrial Diameter				
HAS-BLED score		1.		
Anti-Arrhythmic drugs				
Anti-thrombotic drugs				
<u>COMORBIDITIES</u>				
Hypertension				
Heart Failure				
Coronary Artery Disease				
Diabetes Mellitus				
Obstructive Sleep Apnea				
FOLLOWUP				

Table 02: Procedure A				
rocedure	Site	Perce		
	Left Pulmonary Vein			
	Left Inferior Pulmonary Vein			
	Right Pulmonary Vein			
Ablation	Right Inferior Pulmonary Vein			
ADIALION	Mitral Isthmus			
	Roof lesion			
	Left Atrial Appendage			
	Epicardial Coronary Sinus			
	Comuliantian			



Oklahoma Heart Research ahmarslan7@gmail.com

able 04: Cox regression Analysis						
	Std. Error	Wald	P-Value	Exp(B)	df	
			0.032		2	
,	0.208	0.646	0.421	1.182	1	
}	0.602	6.866	0.009	4.487	1	

### Table 05: AF classes and individual outcomes

to detection of AF 5%		Mean Time to Rehospitalization			Mean Time to recurrence of symptoms						
	95% Cl					95% Cl				95% Cl	
Error	LB	UB	Est.	Std. Error	LB	UB	Est.	Std. Error	LB	UB	
5	3.926	4.496	4.4	0.126	4.153	4.647	4.338	0.117	4.109	4.566	
0	2 690	4 1 6 1	4 074	0.11	2 950	4 200	1 125	0.091	4 266	4 505	
U	3.089	4.101	4.074	0.11	3.859	4.200	7.725	0.081	4.200	4.383	
3	0.827	5.741	2.362	0.911	0.576	4.147	3.474	1.098	1.321	5.627	
5	3.895	4.268	4.179	0.097	3.989	4.369	4.408	0.068	4.274	4.541	

LB: Lower Bound, UB: Upper Bound, CI: Confidence Interval

# **5 CONCLUSIONS**

Hybrid convergent is a safe and effective procedure, showing maximum benefit in patients with paroxysmal atrial fibrillation.

# **6 REFERENCES**

DeLurgio DB, Crossen KJ, Gill J, Blauth C, Oza SR, Magnano AR, et al. Hybrid Convergent Procedure for the Treatment of Persistent and Long-Standing Persistent Atrial Fibrillation: Results of CONVERGE Clinical Trial. Circ: Arrhythmia and Electrophysiology. 2020 Dec;13(12):e009288.

Gersak B, Pernat A, Robic B, Sinkovec M. Low Rate of Atrial Fibrillation Recurrence Verified by Implantable Loop Recorder Monitoring Following a Convergent Epicardial and Endocardial Ablation of Atrial Fibrillation. Journal of Cardiovascular Electrophysiology. 2012 Oct;23(10):1059-66.

 Kurfirst V, Mokra ek A, Bulava A, anadyova J, Hani J, Pe I L. Two-staged hybrid treatment of persistent atrial fibrillation: short-term single-centre results. Interactive CardioVascular and Thoracic Surgery. 2014 Apr

Maclean E, Yap J, Saberwal B, Kolvekar S, Lim W, Wijesuriya N, et al. The convergent procedure versus catheter ablation alone in longstanding persistent atrial fibrillation: A single centre, propensity-matched cohort study. International Journal of Cardiology. 2020 Mar;303:49-53.

# 7 Contact Information